Pure Bioscience files patent for new antimicrobial invention
SAN DIEGO, Dec. 6, 2004 (BUSINESS WIRE) -- Pure Bioscience has filed a utility patent application to protect anhydrous, or crystalline, silver dihydrogen citrate (SDC) antimicrobial compositions, processes of making and methods of use.
The invention is the result of research and development (R&D) headed by Andrew B. Arata, Pure's bioscience R&D director and inventor of SDC, to maximize its novel ionic silver antimicrobial technologies. Current patents cover Pure's aqueous, or liquid, silver dihydrogen citrate. The new patent expands the protected technologies to include solid compositions of this unique antimicrobial that may be mixed with water to form Pure's SDC liquid disinfectant. Preliminary testing demonstrates that crystalline or powdered SDC can be reconstituted to create SDC liquid concentrates and use dilutions. Anhydrous SDC may also be combined with other solutions to provide the same beneficial antimicrobial effect as Pure's current liquid disinfectant.
Michael L. Krall, president and CEO of Pure Bioscience, stated, "Our current ready-to-use dilutions and concentrate forms of SDC liquid offer the highest efficacy and lowest toxicity available, and we should gain additional market advantages in being able to offer the same least-toxic, high efficacy technology in a variety of dry, granular forms. We believe that SDC crystals and powders will expand our reach and make us even more competitive against traditional disinfecting technologies because crystalline and powdered SDC is easy and economical to store and ship."
The company's antimicrobial technologies follow today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. This new molecule, silver dihydrogen citrate, is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets. SDC liquid is colorless, odorless, tasteless, non-caustic and formulates well with other compounds. SDC-based antimicrobial technology is distinguished from competitors in the marketplace because of its superior efficacy combined with reduced toxicity.
Pure currently has Environmental Protection Agency (EPA) registration for its 2400-parts per million (ppm) technical grade SDC concentrate (trade name Axenohl®) as well as for its Axen® and Axen30 hard surface disinfectant products for commercial, industrial and consumer applications including restaurants, homes and medical facilities. In addition to EPA approved uses of SDC technology, Pure, in conjunction with Therapeutics Inc., is pursuing the development and commercialization of Food and Drug Administration-regulated SDC-based healthcare products.
About Pure Bioscience
Pure Bioscience develops and markets technology-based products in the bioscience and water treatment sectors to provide non-toxic solutions to global health challenges. Its proprietary high efficacy/low toxicity bioscience platform technologies represent innovative advances in diverse markets. It is currently a leader in U.S. pharmaceutical water purification with its Fillmaster equipment, and has expanded into residential water treatment with its Nutripure water filtration systems. Based in El Cajon, Calif., and incorporated in 1992, it was formerly named Innovative Medical Services.
###